Patient characteristics
. | . | . | . | . | . | . | . | GvHD . | . | . | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| UPN . | Age, y . | Diagnosis . | Prior treatment . | No. of SCTs . | Graft type . | CD34+/kg × 106 . | Engr day . | Day 30 . | Day 90 . | Status d + 180 . | |
| 845 | 17 | SAA | None | 1 | BM | 3.6 | 11 | 0 | 0 | CR | |
| 891 | 25 | CML | IFN-α, imatinib, HU | 1 | PBSC | 6.4 | 13 | III | NA | Died of infection | |
| 906 | 51 | AML | Chemo | 1 | PBSC | 4.8 | 13 | III | NA | Died of GvHD | |
| 767 | 44 | AML | Chemo, alloSCT | 2 | PBSCTCD/PBSC | 2.00/11.8 | 11 | 0 | NA | Died of relapse | |
| 605 | 32 | CML | Chemo | 1 | BM | 3.2 | 14 | II | I | CR | |
| 727 | 23 | B-ALL | Chemo, synSCT | 1 | synPBSC | 5.2 | 14 | II | NA | Died of GvHD | |
| 816 | 38 | MM | Chemo, XRT | 1 | PBSC | 5.6 | 12 | II | 0 | CR | |
| 903 | 22 | SAA | None | 1 | BM | 2.1 | 15 | I | I | CR | |
| 872 | 36 | AML | Chemo | 2 | PBSCTCD/PBSC | 3.5/4.0 | 13 | II | I | CR | |
| 671 | 16 | B-ALL | Chemo, alloSCT | 1 | PBSC | 8.3 | 8 | I | 0 | CR | |
| 730 | 17 | AML | Chemo, alloSCT | 2 | PBSCTCD/PBSC | 3.0/7.7 | 10 | II | II | Died of infection | |
| 818 | 42 | SAA | None | 1 | PBSC | 4.8 | 14 | I | IV | Died of GvHD | |
| 886 | 22 | MDS | Chemo | 1 | PBSC | 11.4 | 15 | II | I | CR | |
| 852 | 35 | CML | HU | 1 | PBSC | 15.1 | 12 | I | 0 | CR | |
| 908 | 22 | B-ALL | Chemo | 1 | PBSC | 7.4 | 17 | II | III | CR | |
| 603 | 32 | CML | HU | 1 | PBSC | 8.7 | 16 | 0 | 0 | CR | |
| 904 | 42 | CML | HU | 1 | PBSC | 6.3 | 19 | I | I | CR | |
| 860 | 19 | AML | HU, chemo | 2 | PBSCTCD/PBSC | 4.6/9.9 | 13 | II | I | CR | |
| 831 | 50 | CML | Chemo | 2 | PBSCTCD/PBSC | 5.2/7.8 | 19 | I | II | Died of infection | |
| 854 | 24 | CML | IFN-α, chemo, HU | 1 | PBSC | 14.5 | 13 | I | I | CR | |
| 834 | 27 | CML | IFN-α, HU | 1 | PBSC | 9.8 | 18 | 0 | I | CR | |
| 865 | 44 | AML | Chemo | 2 | PBSCTCD/PBSC | 2.4/11.4 | 11 | II | II | CR | |
| 820 | 40 | AML | Chemo | 1 | BM | 2.5 | 17 | II | 0 | CR | |
| 881 | 16 | MDS | Splenectomy | 1 | PBSC | 11.7 | 17 | 0 | 0 | Died of rejection | |
| 822 | 45 | CML | IFN-α, HU | 1 | PBSC | 3.5 | 11 | I | II | CR | |
| 832 | 44 | AML | Chemo | 1 | PBSC | 9.7 | 14 | 0 | I | CR | |
| 804 | 35 | CML | IFN-α | 1 | BM | 2.0 | 20 | II | 0 | Rejection/CR | |
| 893 | 23 | AML | Chemo | 1 | BM | 1.3 | 15 | II | III | Died of GvHD | |
. | . | . | . | . | . | . | . | GvHD . | . | . | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| UPN . | Age, y . | Diagnosis . | Prior treatment . | No. of SCTs . | Graft type . | CD34+/kg × 106 . | Engr day . | Day 30 . | Day 90 . | Status d + 180 . | |
| 845 | 17 | SAA | None | 1 | BM | 3.6 | 11 | 0 | 0 | CR | |
| 891 | 25 | CML | IFN-α, imatinib, HU | 1 | PBSC | 6.4 | 13 | III | NA | Died of infection | |
| 906 | 51 | AML | Chemo | 1 | PBSC | 4.8 | 13 | III | NA | Died of GvHD | |
| 767 | 44 | AML | Chemo, alloSCT | 2 | PBSCTCD/PBSC | 2.00/11.8 | 11 | 0 | NA | Died of relapse | |
| 605 | 32 | CML | Chemo | 1 | BM | 3.2 | 14 | II | I | CR | |
| 727 | 23 | B-ALL | Chemo, synSCT | 1 | synPBSC | 5.2 | 14 | II | NA | Died of GvHD | |
| 816 | 38 | MM | Chemo, XRT | 1 | PBSC | 5.6 | 12 | II | 0 | CR | |
| 903 | 22 | SAA | None | 1 | BM | 2.1 | 15 | I | I | CR | |
| 872 | 36 | AML | Chemo | 2 | PBSCTCD/PBSC | 3.5/4.0 | 13 | II | I | CR | |
| 671 | 16 | B-ALL | Chemo, alloSCT | 1 | PBSC | 8.3 | 8 | I | 0 | CR | |
| 730 | 17 | AML | Chemo, alloSCT | 2 | PBSCTCD/PBSC | 3.0/7.7 | 10 | II | II | Died of infection | |
| 818 | 42 | SAA | None | 1 | PBSC | 4.8 | 14 | I | IV | Died of GvHD | |
| 886 | 22 | MDS | Chemo | 1 | PBSC | 11.4 | 15 | II | I | CR | |
| 852 | 35 | CML | HU | 1 | PBSC | 15.1 | 12 | I | 0 | CR | |
| 908 | 22 | B-ALL | Chemo | 1 | PBSC | 7.4 | 17 | II | III | CR | |
| 603 | 32 | CML | HU | 1 | PBSC | 8.7 | 16 | 0 | 0 | CR | |
| 904 | 42 | CML | HU | 1 | PBSC | 6.3 | 19 | I | I | CR | |
| 860 | 19 | AML | HU, chemo | 2 | PBSCTCD/PBSC | 4.6/9.9 | 13 | II | I | CR | |
| 831 | 50 | CML | Chemo | 2 | PBSCTCD/PBSC | 5.2/7.8 | 19 | I | II | Died of infection | |
| 854 | 24 | CML | IFN-α, chemo, HU | 1 | PBSC | 14.5 | 13 | I | I | CR | |
| 834 | 27 | CML | IFN-α, HU | 1 | PBSC | 9.8 | 18 | 0 | I | CR | |
| 865 | 44 | AML | Chemo | 2 | PBSCTCD/PBSC | 2.4/11.4 | 11 | II | II | CR | |
| 820 | 40 | AML | Chemo | 1 | BM | 2.5 | 17 | II | 0 | CR | |
| 881 | 16 | MDS | Splenectomy | 1 | PBSC | 11.7 | 17 | 0 | 0 | Died of rejection | |
| 822 | 45 | CML | IFN-α, HU | 1 | PBSC | 3.5 | 11 | I | II | CR | |
| 832 | 44 | AML | Chemo | 1 | PBSC | 9.7 | 14 | 0 | I | CR | |
| 804 | 35 | CML | IFN-α | 1 | BM | 2.0 | 20 | II | 0 | Rejection/CR | |
| 893 | 23 | AML | Chemo | 1 | BM | 1.3 | 15 | II | III | Died of GvHD | |
UPN indicates unique patient number; Engr day, engraftment day indicates absolute neutrophil count > 500 μL for 3 consecutive days; SAA, severe aplastic anemia; CR, complete remission; CML, chronic myeloid leukemia; HU, hydroxyurea; Chemo, chemotherapy; NA, not applicable; AML, acute myeloid leukemia; alloSCT, allogenic stem cell transplantation; PBSCTCD, T-cell—depleted PBSCs; B-ALL, acute lymphatic leukemia of B-cell type; synSCT, syngeneic SCT; synPBSC, syngeneic PBSCs; MM, multiple myeloma; XRT, radiotherapy; MDS, myelodysplastic syndrome.